Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 201–300 of 1,006
Hall, M. N. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.10.009 · Cited by 176
The mTOR pathway and its role in human genetic diseases
ROSNER, M., HANNEDER, M., SIEGEL, N., VALLI, A., FUCHS, C., & HENGSTSCHLAGER, M. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.06.001 · Cited by 182
Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition
Umemura, A., Park, E. J., Taniguchi, K., Lee, J. H., Shalapour, S., Valasek, M. A., Aghajan, M., Nakagawa, H., Seki, E., Hall, M. N., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.001 · Cited by 183
Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy
Kong, D., & Yamori, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00891.x · Cited by 184
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
Mallon, R., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C., Santos, E. D., Chen, Z., dos Santos, O., Ayral-Kaloustian, S., Venkatesan, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 172
Characterization of a Cdc42 Protein Inhibitor and Its Use as a Molecular Probe
Hong, L., Kenney, S. R., Phillips, G. K., Simpson, D., Schroeder, C. E., Nöth, J., Romero, E., Swanson, S., Waller, A., Strouse, J. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.435941 · Cited by 168
The role of the p53 tumor suppressor in metabolism and diabetes
Kung, C.-P., & Murphy, M. E. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0324 · Cited by 178
“It is a serine/threonine protein kinase that positively regulates protein synthesis, cell growth and proliferation, and negatively regulates autophagy, which is a key catabolic pathway that is activated under conditions of nutrient starvation (Shaw & Cantley 2006).”
Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK
Moldogazieva, N. T., Mokhosoev, I. M., & Terentiev, A. A. (2020) · Cancers · doi:10.3390/cancers12040862 · Cited by 177
Neergheen, V. S., Bahorun, T., Taylor, E. W., Jen, L.-S., & Aruoma, O. I. (2010) · Toxicology · doi:10.1016/j.tox.2009.10.010 · Cited by 179
“ancer is characterized by aberrant and disrupted intracellular ignaling networks (Shaw and Cantley, 2006), thus targeted inhiition of the protein kinases represent a rational approach in ancer chemoprevention.”
BackgroundCancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Pratheeshkumar, P., Sreekala, C., Zhang, Z., Budhraja, A., Ding, S., Son, Y.-O., Wang, X., Hitron, A., Hyun-Jung, K., Wang, L., et al. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012803833035 · Cited by 178
“Resveratrol has been shown to inhibit the phosphatidylinositol3 kinase (PI-3K)/AKT and the MAPK pathways, two key survival cascades that are frequently aberrantly activated in human cancers [48, 49].”
BackgroundThe Integrative Role of CNS Fuel-Sensing Mechanisms in Energy Balance and Glucose Regulation
Sandoval, D., Cota, D., & Seeley, R. J. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.120806.095256 · Cited by 178
Cancer Metabolism and Drug Resistance
Rahman, M., & Hasan, M. (2015) · Metabolites · doi:10.3390/metabo5040571 · Cited by 170
Musa, J., Orth, M. F., Dallmayer, M., Baldauf, M., Pardo, C., Rotblat, B., Kirchner, T., Leprivier, G., & Grünewald, T. G. P. (2016) · Oncogene · doi:10.1038/onc.2015.515 · Cited by 170
Targeting the AKT protein kinase for cancer chemoprevention
Crowell, J. A., Steele, V. E., & Fay, J. R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0120 · Cited by 170
Dan, H. C., Ebbs, A., Pasparakis, M., Van Dyke, T., Basseres, D. S., & Baldwin, A. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.554881 · Cited by 162
Autophagy in cellular growth control
Wang, R. C., & Levine, B. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.009 · Cited by 170
“Erk kinases phosphorylate GAIP, a Ga interacting protein, whose phosphorylation promotes its GAP activity on the a subunit of the Gi3 protein, which ultimately promotes autophagy [72,74,87].”
BackgroundMoore, T., Beltran, L., Carbajal, S., Strom, S., Traag, J., Hursting, S. D., & DiGiovanni, J. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0022 · Cited by 169
“Evidence suggests that many of these IGF-I-related effects on cellular growth and metabolism involve signaling through the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway (26-28), one of the most commonly altered pathways in human tumors (29-33).”
BackgroundKaadige, M. R., Looper, R. E., Kamalanaadhan, S., & Ayer, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901221106 · Cited by 162
“Further, in many circumstances, nutrients and growth factor signaling coordinate cell growth and survival by controlling the activity of TORC1 complex (1, 2).”
BackgroundPF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Yuan, J., Mehta, P. P., Yin, M.-J., Sun, S., Zou, A., Chen, J., Rafidi, K., Feng, Z., Nickel, J., Engebretsen, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0185 · Cited by 163
“Deregulation of the PI3K pathway by gene mutation has been found in approximately 30% of all human cancers (10).”
BackgroundPhosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
Knowles, M. A., Platt, F. M., Ross, R. L., & Hurst, C. D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9198-3 · Cited by 168
“1) plays a pivotal role in cell growth, proliferation and survival [1] and signalling via this pathway is upregulated in many types of cancer [2, 3].”
BackgroundmTOR signaling in tumorigenesis
Xu, K., Liu, P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.007 · Cited by 165
Targeted therapies for non-small cell lung cancer
Dempke, W. C. M., Suto, T., & Reck, M. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.10.012 · Cited by 164
Ragulator and SLC38A9 activate the Rag GTPases through noncanonical GEF mechanisms
Shen, K., & Sabatini, D. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811727115 · Cited by 158
Levy, D. S., Kahana, J. A., & Kumar, R. (2009) · Blood · doi:10.1182/blood-2008-02-137737 · Cited by 159
Zitzmann, K., De Toni, E. N., Brand, S., Göke, B., Meinecke, J., Spöttl, G., Meyer, H. H. D., & Auernhammer, C. J. (2007) · Neuroendocrinology · doi:10.1159/000100057 · Cited by 160
“The phosphatidylinositol-3-kinase (PI(3)K)/Akt/mTOR pathway is crucial for the regulation of cell survival and proliferation. Growth factors of the insulin family, including insulin, insulin-like growth factor I (IGF-I) and IGF-II, initiate PI(3)K/Akt/mTOR signaling by activating insulin/IGF-I receptor tyrosine kinase…”
BackgroundRegulatory Coordination between Two Major Intracellular Homeostatic Systems
Dokladny, K., Zuhl, M. N., Mandell, M., Bhattacharya, D., Schneider, S., Deretic, V., & Moseley, P. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.462408 · Cited by 158
“Subsequently, Akt phosphorylates and inactivates tuberin, leading to increased mTOR activity (66).”
BackgroundPotential role ofFox O 1 and m TORC 1 in the pathogenesis ofWestern diet‐induced acne
Melnik, B. C., & Zouboulis, C. C. (2013) · Experimental Dermatology · doi:10.1111/exd.12142 · Cited by 162
The role of mTOR in the management of solid tumors: An overview
Strimpakos, A. S., Karapanagiotou, E. M., Saif, M. W., & Syrigos, K. N. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.09.006 · Cited by 160
Zhang, M., Cui, S., Mao, B., Zhang, Q., Zhao, J., Zhang, H., Tang, X., & Chen, W. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2036693 · Cited by 171
A model of the mitochondrial basis of bipolar disorder
Morris, G., Walder, K., McGee, S. L., Dean, O. M., Tye, S. J., Maes, M., & Berk, M. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.014 · Cited by 162
Second AKT: The rise of SGK in cancer signalling
Bruhn, M. A., Pearson, R. B., Hannan, R. D., & Sheppard, K. E. (2010) · Growth Factors · doi:10.3109/08977194.2010.518616 · Cited by 160
Wesolowski, S. R., Regnault, T. R. H., Brown, L. D., Rozance, P. J., Keng, J. A., Roper, M. D., Wilkening, R. B., Hay, W. W., & Friedman, J. E. (2009) · Endocrinology · doi:10.1210/en.2008-1789 · Cited by 174
“mTOR phosphorylates 4EBP1 and S6K, which increases mRNA translation (13, 14).”
InfluentialThe mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes
Brown, N. F., Stefanović-Račić, M., SIPULA, I. J., & Perdomo, G. (2007) · Metabolism · doi:10.1016/j.metabol.2007.06.016 · Cited by 174
“Its role in the regulation of cell growth has been extensively studied and is well defined [2].”
BackgroundConvergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Jacobsen, K., Bertran-Alamillo, J., Molina, M. A., Teixidó, C., Karachaliou, N., Pedersen, M. H., Castellví, J., Garzón, M., Codony-Servat, C., Codony-Servat, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00450-6 · Cited by 158
Xu, Z., Zhu, C., Chen, C., Zong, Y., Feng, H., Liu, D., Feng, W., Zhao, J., & Lu, A. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1010-2 · Cited by 159
The Rheb–mTOR Pathway Is Upregulated in Reactive Astrocytes of the Injured Spinal Cord
Codeluppi, S., Svensson, C. I., Hefferan, M. P., Valencia, F., Silldorff, M. D., Oshiro, M., Marsala, M., & Pasquale, E. B. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4103-08.2009 · Cited by 154
“Nevertheless, it will be important to carefully examine the in vivo effects of rapamycin on functional recovery after different types of nervous system injury, because of the complexities of the mTORC1 pathway and its importance in regulating the physiology of different cell types in the damaged nervous system (Sabati…”
BackgroundMethodInfluentialCancer invasion and resistance: interconnected processes of disease progression and therapy failure
Alexander, S., & Friedl, P. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.11.003 · Cited by 182
RAS signaling pathways, mutations and their role in colorectal cancer
Zenonos, K. (2013) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v5.i5.97 · Cited by 156
Wang, X., Yue, P., Kim, Y. A., Fu, H., Khuri, F. R., & Sun, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1522 · Cited by 167
Sun, Y., Liu, S., Qiao, Z., Shang, Z., Xia, Z., Niu, X., Qian, L., Zhang, Y., Fan, L.-Y., Cao, C., et al. (2017) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.06.005 · Cited by 157
Thorn, S., Rozance, P., Brown, L., & Hay, W. (2011) · Seminars in Reproductive Medicine · doi:10.1055/s-0031-1275516 · Cited by 153
“mTOR phosphorylates eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and ribosomal S6 kinase (S6K), which increase mRNA translation.(76,77) Interestingly, mTOR, 50 adenosine monophosphate-activated protein kinase (AMPK), and AKT activation (AKT or protein kinase beta, PKB, a serine/threonine prote…”
Targeting PI3 kinase in cancer
Bauer, T. M., Patel, M. R., & Infante, J. R. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.006 · Cited by 161
The Complexes of Mammalian Target of Rapamycin
Zhou, H., & Huang, S. (2010) · Current Protein & Peptide Science · doi:10.2174/138920310791824093 · Cited by 145
Fu, L., Kim, Y.-A., Wang, X., Wu, X., Yue, P., Lonial, S., Khuri, F. R., & Sun, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2190 · Cited by 162
Metformin Targets Multiple Signaling Pathways in Cancer
Lei, Y., Yi, Y., Liu, Y., Liu, X., Keller, E. T., Qian, C.-N., Zhang, J., & Lu, Y. (2017) · Chinese Journal of Cancer · doi:10.1186/s40880-017-0184-9 · Cited by 152
“The combination of TSC1 and TSC2 functions as a tumor inhibitory complex that suppresses mTOR activity.”
BackgroundmTOR kinase inhibitors as potential cancer therapeutic drugs
Sun, S.-Y. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.017 · Cited by 144
“Introduction Mammalian target of rapamycin (mTOR) belongs to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family that also includes PI3K, ataxia–telangiectasia mutated (ATM), ATM- and Rad3-related (ATR), DNA-dependent protein kinase (DNA-PK) and suppressor of morphogenesis in genitalia-1 (SMG-1) [1].…”
BackgroundInfluentialmTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer
Sodi, V. L., Khaku, S., Krutilina, R., Schwab, L. P., Vocadlo, D. J., Seagroves, T. N., & Reginato, M. J. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0536 · Cited by 148
“The PI3K–AKT pathway directly contributes to altered metabolism of cancer cells by inducing cells to take up excess glucose via regulation of glucose transporters (30, 3) and via activation of the mTOR signaling pathway (31).”
BackgroundDietary intervention in acne: Attenuation of increased mTORC1 signaling promoted by Western diet
Melnik, B. (2012) · Dermato-Endocrinology · doi:10.4161/derm.19828 · Cited by 142
Lin, A., Piao, H.-L., Zhuang, L., Sarbassov, D. D., Ma, L., & Gan, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1729 · Cited by 149
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis
Mei, Z., Duan, C., Li, C. B., Cui, L., & Ogino, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw264 · Cited by 165
Clinical relevance of colorectal cancer molecular subtypes
Rodríguez-Salas, N., Dominguez, G., Barderas, R., Mendiola, M., García‐Albéniz, X., Maurel, J., & Batlle, J. F. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.007 · Cited by 171
Deregulation of Signaling Pathways in Acute Myeloid Leukemia
Scholl, C., Gilliland, D. G., & Fröhling, S. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.004 · Cited by 163
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
Gan, B., Lim, C., Chu, G., Hua, S., Ding, Z., Collins, M., Hu, J., Jiang, S., Fletcher-Sananikone, E., Zhuang, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.019 · Cited by 144
“These observations hold important therapeutic implications in that, in specific genotypic contexts, mTORC1 inhibitor treatment alone might enhance tumorigenesis in mTORC1 hyperactivation-driven tumors by stimulating PI3K-AKT-depen- dent survival and cell cycle entry, thereby prompting calls for combination therapeutic…”
InfluentialWang, X., Liu, J. Z., Hu, J. X., Wu, H., Li, Y. L., Chen, H. L., Bai, H., & Hai, C. X. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.019 · Cited by 157
“The Akt /mTOR signal has also been shown to play critical roles in tumorigenesis of a variety of cell types [31].”
Backgroundvan Dam, T. J. P., Zwartkruis, F. J. T., Bos, J. L., & Snel, B. (2011) · Journal of Molecular Evolution · doi:10.1007/s00239-011-9469-9 · Cited by 167
“…oncogenes and tumor suppressors such as phosphoinositide-3-kinase (PI3K), phosphoinositide-dependent kinase 1 (PDK1), phosphatase and tensin homolog (PTEN) and protein kinase B (PKB) (also known as AKT) (Engelman et al. 2006; Ma and Blenis 2009; Menon and Manning 2008; Shaw and Cantley 2006).”
BackgroundER Stress Inhibits mTORC2 and Akt Signaling Through GSK-3β–Mediated Phosphorylation of Rictor
Chen, C.-H., Shaikenov, T., Peterson, T. R., Aimbetov, R., Bissenbaev, A. K., Lee, S.-W., Wu, J., Lin, H.-K., & Sarbassov, D. D. (2011) · Science Signaling · doi:10.1126/scisignal.2001731 · Cited by 139
Opel, D., Westhoff, M., Bender, A., Braun, V., Debatin, K., & Fulda, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6769 · Cited by 155
“Whereas PI3K is presumed to activate most of its downstream targets via the Akt protein, the network rapidly diversifies into many distinct arms thereafter, one of which leads to the activation of the mammalian target of rapamycin (mTOR) and its targets (15).”
BackgroundResponse to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
Stacchiotti, S., Tamborini, E., Marrari, A., Brich, S., Rota, S. A., Orsenigo, M., Crippa, F., Morosi, C., Gronchi, A., Pierotti, M. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2050 · Cited by 145
Akt as a therapeutic target in cancer
Steelman, L. S., Stadelman, K. M., Chappell, W. H., Horn, S., Bäsecke, J., Cervello, M., Nicoletti, F., Libra, M., Stivala, F., Martelli, A. M., et al. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.9.1139 · Cited by 140
“PTEN (phosphatase and tensin homolog deleted on chromosome ten) is primarily a lipid phosphatase that removes the 3-phosphate from the PI3K lipid product PtdIns (3,4,5) P 3 to produce PtdIns (4,5) P 2 which prevents Akt activation [4,73-77] .”
Yip, P. Y. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.01.04 · Cited by 176
Cell Survival and Apoptosis Signaling as Therapeutic Target for Cancer: Marine Bioactive Compounds
Kalimuthu, S., & Kim, S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14022334 · Cited by 164
Epac: effectors and biological functions
Roscioni, S., Elzinga, C., & Schmidt, M. (2008) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-007-0246-7 · Cited by 160
“Importantly, PLD-generated PA is implicated in the regulation of the mammalian target of rapamycin (mTOR; Fang et al. 2001), a phosphatidylinositol 3-kinase (PI 3kinase)-regulated effector protein known to be involved in the regulation of gene transcription and cell-cycle progression ( Shaw and Cantley 2006; Foster 20…”
BackgroundDopaminergic pathway reconstruction by Akt/Rheb‐induced axon regeneration
Kim, S. R., Chen, X., Oo, T. F., Kareva, T., Yarygina, O., Wang, C., During, M., Kholodilov, N., & Burke, R. E. (2011) · Annals of Neurology · doi:10.1002/ana.22383 · Cited by 143
Targeting inflammatory pathways for tumor radiosensitization
Deorukhkar, A., & Krishnan, S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.039 · Cited by 156
“The PI3K/Akt pathway is constitutively activated in various cancers [145, 146], plays a critical role in promoting cell growth, and mediates TNFα-mediated NFκB activation [144, 147].”
BackgroundKonstantinidou, G., Bey, E. A., Rabellino, A., Schuster, K., Maira, M. S., Gazdar, A. F., Amici, A., Boothman, D. A., & Scaglioni, P. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0823 · Cited by 142
“has been implicated in human cancer (2, 3).”
BackgroundAghajan, M., Jonai, N., Flick, K. M., Fu, F., Luo, M., Cai, X., Ouni, I., Pierce, N. W., Tang, X., Lomenick, B., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1645 · Cited by 150
Dolly, S. O., Wagner, A. J., Bendell, J. C., Kindler, H. L., Krug, L. M., Seiwert, T. Y., Zauderer, M. G., Lolkema, M. P., Apt, D., Yeh, R.-F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2225 · Cited by 140
“The PI3K pathway plays a role in glucose homeostasis and has demonstrated an impact on the Glut1 transporter (31).”
BackgroundTargeting mitochondria in cancer: current concepts and immunotherapy approaches
Pustylnikov, S., Costabile, F., Beghi, S., & Facciabene, A. (2018) · Translational research · doi:10.1016/j.trsl.2018.07.013 · Cited by 145
“Activation of the phosphatidylinositol 3-kinase (PI3K)—phosphatase PTEN—AKT signal transduction pathway drives changes in metabolism to promote cancer cell growth and proliferation.(38) Indeed, AKT pharmacologic inhibition enables TIL expansion.”
Leucine signaling in the pathogenesis of type 2 diabetes and obesity
Melnik, B. C. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i3.38 · Cited by 140
Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
Ferrín, G., Guerrero, M., Amado, V., Rodríguez-Perálvarez, M., & De la Mata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041266 · Cited by 135
Ionization Properties of Phosphatidylinositol Polyphosphates in Mixed Model Membranes
Kooijman, E. E., King, K. E., Gangoda, M., & Gericke, A. (2009) · Biochemistry · doi:10.1021/bi9008616 · Cited by 140
Hewish, M., Chau, I., & Cunningham, D. (2009) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489209787002515 · Cited by 141
“The Ras/Raf and PI3K pathways then converge at the mammalian target of rapamycin, mTOR, which again can cause effects on cell growth [33, 47, 48].”
BackgroundHuman T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis
Kannian, P., & Green, P. L. (2010) · Viruses · doi:10.3390/v2092037 · Cited by 139
Apontes, P., Leontieva, O. V., Demidenko, Z. N., Li, F., & Blagosklonny, M. V. (2011) · Oncotarget · doi:10.18632/oncotarget.248 · Cited by 149
“Cancer cells are characterized by dysregulation of the PI-3K/mTOR pathway [23-26].”
BackgroundEmerging roles for Rab family GTPases in human cancer
Chia, W.-J., & Tang, B. L. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.10.001 · Cited by 150
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent
Wang, J., Tannous, B. A., Poznansky, M. C., & Chen, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105010 · Cited by 144
The mTOR Pathway in Hepatic Malignancies
Bhat, M., Sonenberg, N., & Gores, G. J. (2013) · Hepatology · doi:10.1002/hep.26323 · Cited by 133
“Up-regulation of the mTOR pathway is seen in approximately 70% of all types of cancers.(13) The importance of the mTOR pathway in carcinogenesis is further underscored by the presence of mutations along the mTOR pathway in familial cancer syndromes.”
BackgroundRelationship of electrophilic stress to aging
Zimniak, P. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.039 · Cited by 132
“TOR signaling is essential during growth [90,91] but, if over-activated in adulthood, may cause inappropriate growth/ proliferation which leads to loss of homeostasis and to aging [57,92,93].”
BackgroundCellular and molecular mechanisms in cancer immune escape: a comprehensive review
Bhatia, A., & Kumar, Y. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865519 · Cited by 131
IQGAP3 regulates cell proliferation through the Ras/ERK signalling cascade
Nojima, H., Adachi, M., Matsui, T., Okawa, K., Tsukita, S., & Tsukita, S. (2008) · Nature Cell Biology · doi:10.1038/ncb1757 · Cited by 143
A somatic activating NRAS variant associated with kaposiform lymphangiomatosis
Barclay, S. F., Inman, K. W., Luks, V. L., McIntyre, J. B., Al‐Ibraheemi, A., Church, A. J., Pérez‐Atayde, A. R., Mangray, S., Jeng, M., Kreimer, S., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0390-0 · Cited by 141
Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
Laurent-Puig, P., Lievre, A., & Blons, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0905 · Cited by 133
“genesis through deregulation of protein synthesis, cell cycle progression, apoptosis angiogenesis, and altered metabolism (5).”
BackgroundZhu, Y., Yang, T., Duan, J., Mu, N., & Zhang, T. (2019) · Aging · doi:10.18632/aging.101766 · Cited by 142
“Recent studies illustrated that mTOR protein kinase is a kind of critical growth-control node, as a receiver of stimulatory signals from Ras and PI3K downstream [59].”
BackgroundMechanism and Management of AKT Inhibitor-Induced Hyperglycemia
Crouthamel, M.-C., Kahana, J. A., Korenchuk, S., Zhang, S.-Y., Sundaresan, G., Eberwein, D. J., Brown, K. K., & Kumar, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1253 · Cited by 125
“Dysregulation of insulin-like growth factor-I receptor (IGF-IR) signaling and the phosphoinositide 3-kinase (PI3K)/AKT/ mammalian target of rapamycin (mTOR) pathway has been implicated in many human cancers (1, 2).”
BackgroundNovel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 139
Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death
Xia, H.-G., Najafov, A., Geng, J., Galan-Acosta, L., Han, X., Guo, Y., Shan, B., Zhang, Y., Norberg, E., Zhang, T., et al. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201503044 · Cited by 122
Hou, G., Xue, L., Lu, Z., Fan, T., Tian, F., & Xue, Y. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.01.026 · Cited by 138
S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1
Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B., & Karni, R. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.020 · Cited by 129
“Insulin/IGF-1 and EGF activate their corresponding receptors leading to activation of several mitogenic signaling cascades, among them the Ras-Raf-MAPK-ERK and the PI3K-AktmTOR pathways (Shaw and Cantley, 2006) (Yuan and Cantley, 2008) (Mendoza et al., 2011).”
BackgroundMethodLin, Y.-W., Beharry, Z. M., Hill, E. G., Song, J. H., Wang, W., Xia, Z., Zhang, Z., Aplan, P. D., Aster, J. C., Smith, C. D., et al. (2009) · Blood · doi:10.1182/blood-2009-07-233445 · Cited by 142
P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell Death
Bian, S., Sun, X., Bai, A., Zhang, C., Li, L., Enjyoji, K., Junger, W. G., Robson, S. C., & Wu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060184 · Cited by 123
“mTOR is a well-known key player in many critical cellular processes such as proliferation, survival, autophagy, and metabolism [22,43].”
Negative regulation of autophagy
Liang, C. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.115 · Cited by 130
“metabolic signaling upstream of mTORC1 seems profoundly altered in many tumors.(33) The oncogenic components in the PI3K–AKTmTOR-mediated anabolic pathway are constitutively active in most cancers, whereas molecules known to”
Back to basics: how natural products can provide the basis for new therapeutics
Deorukhkar, A., Krishnan, S., Sethi, G., & Aggarwal, B. B. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.11.1753 · Cited by 139
“The Ras, PI3K and mTOR signaling pathways are some of the most frequently targeted pathways in human cancers [179] .”
Ghislat, G., Patron, M., Rizzuto, R., & Knecht, E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.365767 · Cited by 126
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Mellinghoff, I. K., Cloughesy, T. F., & Mischel, P. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1992 · Cited by 148
Bianchini, A., Loiarro, M., Bielli, P., Busà, R., Paronetto, M. P., Loreni, F., Geremia, R., & Sette, C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn221 · Cited by 126
Role of RAS in the Regulation of PI 3-Kinase
Castellano, E., & Downward, J. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_56 · Cited by 149
“mechanisms, such as mutations in RAS, loss of GAP proteins, overexpression of RTKs (EGFR, ERBB2), and also by mutations or amplifications in any of their effector molecules (Vivanco and Sawyers 2002; Hennessy et al. 2005; Shaw and Cantley 2006; Jia et al. 2009).”
BackgroundVijayaraj, P., Kröger, C., Reuter, U., Windoffer, R., Leube, R. E., & Magin, T. M. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200906094 · Cited by 128
“, 2009) and that mTORC1 is nutrient sensitive (Shaw and Cantley, 2006), we were prompted to investigate upstream regulators of mTORC1 that might depend on keratins.”
BackgroundThe Biological Role of PI3K Pathway in Lung Cancer
Sarris, E., Saif, M., & Syrigos, K. (2012) · Pharmaceuticals · doi:10.3390/ph5111236 · Cited by 128
Inhibition of Glycolytic Enzymes Mediated by Pharmacologically Activated p53
Zawacka-Pankau, J., Grinkevich, V. V., Hünten, S., Nikulenkov, F., Gluch, A., Li, H., Enge, M., Kel, A., & Selivanova, G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240812 · Cited by 126
García, M. R., Foretz, M., Viollet, B., Prieto, A., Fraga, M., Costoya, J. A., & Señarís, R. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-0861 · Cited by 135
“These signaling pathways are frequently activated in human astrocytomas (13).”
Background
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.